What are the treatment guidelines for managing vomiting in an otherwise healthy adult?

Treatment Guidelines for Vomiting in Otherwise Healthy Adults

Start with oral rehydration solution (ORS) for mild-to-moderate dehydration and initiate dopamine receptor antagonists (metoclopramide, prochlorperazine, or haloperidol) as first-line antiemetic therapy, escalating to 5-HT3 antagonists (ondansetron) only if symptoms persist beyond 4 weeks. 1

Initial Assessment and Stabilization

Fluid Rehydration Strategy:

• Administer reduced-osmolarity ORS as first-line therapy for mild-to-moderate dehydration (3-9% fluid deficit): 2-4 liters over 3-4 hours for adults ≥30 kg 1
• Reserve isotonic IV crystalloids (lactated Ringer's or normal saline) for severe dehydration (≥10% deficit), shock, altered mental status, or failure of oral intake 1
• Continue breastfeeding throughout illness in nursing mothers 1

Laboratory Evaluation:

• Obtain complete blood count, serum electrolytes, glucose, liver function tests, lipase, and urinalysis to exclude metabolic causes and assess dehydration 1, 2
• Check for hypercalcemia, hypothyroidism, and Addison's disease if clinically indicated 1, 2
• Obtain urine pregnancy test immediately in any woman of reproductive potential—failure to do so is the single most critical initial omission 1
• Screen for cannabis use, as Cannabis Hyperemesis Syndrome requires 6 months of cessation for definitive diagnosis 1, 2

Critical Red Flags Requiring Immediate Escalation:

• High fever (>38.5°C) with frank blood in stools (dysentery) 3
• Bilious or bloody vomiting 4, 5
• Altered mental status or toxic appearance 4, 5
• Signs of mechanical bowel obstruction 1, 2

Stepwise Pharmacologic Management

First-Line: Dopamine Receptor Antagonists (Days 1-28)

Administer on a scheduled (around-the-clock) basis rather than PRN, as prevention is far easier than treating established vomiting. 1, 2

Choose one of the following:

• Metoclopramide 10-20 mg IV or PO every 6-8 hours—particularly effective for gastric stasis and gastroparesis by promoting gastric emptying 1, 2, 6
• Prochlorperazine 10 mg IV or PO every 6-8 hours—alternative dopamine antagonist when metoclopramide is unsuitable 1, 2
• Haloperidol 0.5-2 mg IV or PO every 4-6 hours—offers different receptor profile for additional anti-dopaminergic effect 1, 2

Titrate to maximum benefit and tolerance before adding additional agents. 1, 2

Monitor for extrapyramidal symptoms, particularly in young males; treat with diphenhydramine 50 mg IV if they develop. 1, 2

Second-Line: Add 5-HT3 Antagonist (After ≥4 Weeks of First-Line)

Add ondansetron 4-8 mg IV or PO every 8 hours (maximum 16 mg per dose) without discontinuing the dopamine antagonist—this targets a different emetic pathway and provides complementary coverage 1, 2

Monitor for QTc prolongation, especially when combining with other QT-prolonging agents. 1, 2

Consider sublingual tablets to improve absorption in actively vomiting patients. 1

Third-Line: Adjunctive Agents (Concurrent with First-/Second-Line)

When symptoms persist after 48-72 hours of second-line therapy, add agents from different pharmacologic classes rather than replacing existing therapy: 1, 2

• Dexamethasone 4-10 mg IV or PO twice daily—for severe or central-nervous-system-related nausea; combination with ondansetron is superior to either agent alone (Category 1 evidence) 1, 2
• Lorazepam 0.5-1 mg PO or IV every 4-6 hours—when anxiety contributes to nausea 1, 2
• Anticholinergic agents (e.g., scopolamine) or antihistamines (e.g., meclizine) for additional symptom control 1, 2

Fourth-Line: Refractory Management

For intractable vomiting unresponsive to combination therapy:

• Olanzapine 10 mg orally once daily—provides high efficacy through broad receptor activity (dopamine, serotonin, histamine) 1
• Dronabinol 2.5-7.5 mg PO every 4 hours as needed—FDA-approved cannabinoid for refractory nausea 1, 2
• Continuous IV or subcutaneous infusion of antiemetics 1, 2
• Multiple concurrent agents on alternating schedules 1, 2

Route of Administration Considerations

When oral intake is not feasible due to ongoing vomiting, use alternative routes (rectal, sublingual, IV, IM) to ensure drug delivery. 1, 2

Dietary Management

• Resume age-appropriate normal diet during or immediately after completion of rehydration 1
• Small, frequent, bland meals using high-protein and low-fat content 6
• Avoid high-sugar fluids (fruit juices, sports drinks, soft drinks) for rehydration, as they are inappropriate in standard gastroenteritis management 1
• Avoid trigger foods (spicy, fatty, acidic, fried foods, and foods with strong odors) 6

Treatment of Specific Underlying Causes

If gastroparesis or gastritis is suspected:

• Continue metoclopramide as it promotes gastric emptying 1
• Add proton pump inhibitor or H2 receptor antagonist 1, 2

If metabolic abnormalities are identified:

• Correct hypercalcemia and treat dehydration 1
• Address electrolyte imbalances, particularly hypokalemia and hypomagnesemia, which are common after prolonged vomiting 1, 2

If Cannabis Hyperemesis Syndrome is suspected:

• Do not stigmatize patients—offer abortive and prophylactic therapy even with ongoing use, as treatments can still be effective 1, 2
• Definitive diagnosis requires 6 months of cannabis cessation 1

Critical Pitfalls to Avoid

• Never use antiemetics in suspected mechanical bowel obstruction, as this can mask progressive ileus and gastric distension 1, 2, 6
• Do not replace one antiemetic with another; instead, add agents from different drug classes to engage multiple neuroreceptor pathways 1, 2
• Avoid repeated endoscopy or imaging unless new symptoms develop 1, 2
• Metoclopramide carries a black box warning for tardive dyskinesia with prolonged use—monitor for extrapyramidal side effects 6
• Antimotility agents (loperamide) should not be given to patients with inflammatory diarrhea or fever at any age 1

Reassessment and Follow-Up

If nausea persists beyond one week on scheduled antiemetics, reassess the underlying cause and consider medication rotation or adding agents from different drug classes. 6

Systematically reassess for non-pharmacologic causes before escalating therapy: brain metastases, electrolyte disturbances, tumor infiltration of the gastrointestinal tract, and other comorbidities 1

Persistently abnormal liver chemistries after symptom resolution should prompt evaluation for viral hepatitis, autoimmune hepatitis, or drug-induced liver injury. 1